David Langleben
Dr. David Langleben is a Professor of Medicine at 海角社区 and former Director of the Cardiology Division of the Jewish General Hospital. He founded and directs the Centre for Pulmonary Vascular Disease, an internationally recognized resource for patient care, teaching, and research. He is also a Project Director at the Lady Davis Institute for Medical Research.聽
Dr. Langleben鈥檚 research focuses on the vascular biology of pulmonary hypertension. He has studied endothelial dysfunction in the disorder, at the cellular, organ, and whole-body level. He and his colleagues were the first to identify endothelin-1 as a mediator in pulmonary hypertension. Over the聽following 20 years, this discovery led to the development of several approved therapies that have benefitted thousands of patients. His group has gone on to study the clearance of endothelin-1 in pulmonary hypertension and to examine mechanisms that control its synthesis. Recent work has focused on the effects of bone morphogenic proteins and other members of the transforming growth factor-尾 family of molecules on the control of endothelin-1 production.
Another major focus has been measuring the loss of lung microvessels in pulmonary hypertension and assessing its impact on prognosis, response to therapy, and exercise capacity.